BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 15000529)

  • 1. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
    Flink MT; Atchison WD
    J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.
    Flink MT; Atchison WD
    J Physiol; 2002 Sep; 543(Pt 2):567-76. PubMed ID: 12205190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular immunology of voltage-gated calcium channel and Lambert-Eaton myasthenic syndrome].
    Iwasa K; Komai K; Yasukawa Y; Maruta T; Takamori M
    Nihon Rinsho; 1997 Dec; 55(12):3322-30. PubMed ID: 9436458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
    Takamori M
    J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive transfer of Lambert-Eaton myasthenic syndrome induces dihydropyridine sensitivity of ICa in mouse motor nerve terminals.
    Xu YF; Hewett SJ; Atchison WD
    J Neurophysiol; 1998 Sep; 80(3):1056-69. PubMed ID: 9744921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of Lambert-Eaton myasthenic syndrome immunoglobulin for nerve terminal calcium channels.
    Hewett SJ; Atchison WD
    Brain Res; 1992 Dec; 599(2):324-32. PubMed ID: 1363289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome.
    Takamori M; Komai K; Iwasa K
    Am J Med Sci; 2000 Apr; 319(4):204-8. PubMed ID: 10768604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy.
    Takamori M; Maruta T; Komai K
    Neurosci Res; 2000 Mar; 36(3):183-91. PubMed ID: 10683522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder.
    Vincent A; Lang B; Newsom-Davis J
    Trends Neurosci; 1989 Dec; 12(12):496-502. PubMed ID: 2480664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulations of active zone structure and function at mammalian NMJs predict that loss of calcium channels alone is not sufficient to replicate LEMS effects.
    Ginebaugh SP; Badawi Y; Laghaei R; Mersky G; Wallace CJ; Tarr TB; Kaufhold C; Reddel S; Meriney SD
    J Neurophysiol; 2023 May; 129(5):1259-1277. PubMed ID: 37073966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteins synaptotagmin and syntaxin are not general targets of Lambert-Eaton myasthenic syndrome autoantibody.
    Hajela RK; Atchison WD
    J Neurochem; 1995 Mar; 64(3):1245-51. PubMed ID: 7861157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dosage and specificity of anti-calcium channel antibodies in Lambert-Eaton myasthenic syndrome].
    Martin-Moutot N; de Haro L; Seagar M
    Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S28-34. PubMed ID: 15269657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse.
    Waterman SA; Lang B; Newsom-Davis J
    Ann Neurol; 1997 Aug; 42(2):147-56. PubMed ID: 9266723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lambert-Eaton Myasthenic Syndrome].
    Matsuo H
    Brain Nerve; 2024 May; 76(5):630-634. PubMed ID: 38741506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lambert-Eaton myasthenic syndrome (LEMS)].
    Suzuki S
    Brain Nerve; 2010 Apr; 62(4):419-26. PubMed ID: 20420183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of non-L-, non-N-type (Q-like) Ca2+ channels by Lambert-Eaton myasthenic syndrome (LEMS) antibodies in rat insulinoma RINm5F cells.
    Magnelli V; Grassi C; Parlatore E; Sher E; Carbone E
    FEBS Lett; 1996 May; 387(1):47-52. PubMed ID: 8654565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective action of myasthenic syndrome antibodies on calcium channels in a rodent neuroblastoma x glioma cell line.
    Peers C; Lang B; Newsom-Davis J; Wray DW
    J Physiol; 1990 Feb; 421():293-308. PubMed ID: 2161458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of synaptotagmin with voltage gated calcium channels: a role in Lambert-Eaton myasthenic syndrome?
    David P; Martin-Moutot N; Leveque C; el Far O; Takahashi M; Seagar MJ
    Neuromuscul Disord; 1993; 3(5-6):451-4. PubMed ID: 8186692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.
    Lang B; Pinto A; Giovannini F; Newsom-Davis J; Vincent A
    Ann N Y Acad Sci; 2003 Sep; 998():187-95. PubMed ID: 14592874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lambert-Eaton syndrome antibodies inhibit acetylcholine release and P/Q-type Ca2+ channels in electric ray nerve endings.
    Satoh Y; Hirashima N; Tokumaru H; Takahashi MP; Kang J; Viglione MP; Kim YI; Kirino Y
    J Physiol; 1998 Apr; 508 ( Pt 2)(Pt 2):427-38. PubMed ID: 9508807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.